HEMGENIX is the first-ever FDA-approved gene therapy for hemophilia B. It is a one-time infusion that offers elevated factor IX levels for years.

HEMGENIX is the first ever FDA approved gene therapy for hemophilia B. By addressing the root cause, it offers elevated FIX levels for years. Please see Important Safety Information and full …

HEMGENIX is the first-ever FDA-approved gene therapy for hemophilia B. A one-time infusion could offer elevated factor IX levels for years. Please see Important Safety Information and full …

HEMGENIX ®, etranacogene dezaparvovec-drlb, is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with Hemophilia B (congenital Factor IX …

HEMGENIX (etranacogene dezaparvovec-drlb) combines a liver-directed AAV5 vector, the highly active factor IX-Padua gene variant, and a liver-specific promoter. Please see Important Safety …

For hemophilia B patients, provide superior bleed protection with HEMGENIX as well as elevated and sustained factor IX levels that last for years. Please see Important Safety Information and …

Find resources about HEMGENIX services and treatment options. Read the answers to some frequently asked questions about HEMGENIX. Please see Important Safety Information and …

Learn about storing and handling HEMGENIX, how to prepare for administration, and what to do during and after the infusion of HEMGENIX. Please see Important Safety Information and full …

HEMGENIX ®, etranacogene dezaparvovec-drlb, is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with Hemophilia B (congenital Factor IX …

Learn how to get started on HEMGENIX and what to expect during your treatment journey. Please see Important Safety Information and full Prescribing Information on website.